Unquoted Biotechs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Unquoted Biotechs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob zagorin who wrote (197)	10/14/2007 2:10:29 PM
From: DewDiligence_on_SI	of 253

5) GTC Biotherapeutics (GTCB): Recently received good news of fast-track FDA designation & permission for rolling BLA app for Atryn, which is already approved in Europe & is produced by GTC's novel transgenic protein technology, which allows complex human proteins to be produced & purified in goats by inserting human DNA into the animals. GTC anticipates filing the initial sections with the FDA in 4Q07 and completing the rolling submission after all clinical data is gathered, analyzed, and available for the BLA, which is planned by end 1Q08. This is slightly out of date: the BLA submission has been pushed back to mid 2008: siliconinvestor.com Regards, Dew

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next